The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

The Changing Landscape of Aortic Valve Replacement in the United States

DOI: 10.4244/EIJ-D-19-00381

1. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
2. Massachussets General Hospital, Harvard Medical School, Boston, MA
3. Columbia University Medical Center, New York, NY
4. Vanderbilt University Medical Center, Nashville, TN
5. Henry Ford Health System, Detroit, MI
6. Cleveland Clinic Foundation, Cleveland, OH
7. Rhode Island Hospital, Brown University, Providence, RI
8. Massachussets General Hospital, Harvard Medical School, Boston, MA
9. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA
10. Mayo Clinic, Rochester, MN
11. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
12. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Cardiovascular Research Foundation, New York, NY
13. Brigham and Women's Hospital Heart & Vascular Centre, Harvard Medical School, Boston, MA, United States
Disclaimer:

As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.

To read the full content of this article, please log in to download the PDF.

With the growing utilization of TAVR over the last decade, it is important to examine the impact of adoption of TAVR on the number of SAVRs and total number of AVRs. We observed a linear increase in the total number of AVRs performed in the United States that was mainly driven by a marked diffusion of TAVR, whereas the number of SAVRs remained relatively stable. The number of TAVRs increased in all age categories. In contrast, the number of SAVRs increased modestly in those aged <75 years and declined in the older age categories. Our results highlight a previously untreated or undertreated population of patients that were not suitable candidates for surgery but are now being treated with TAVR.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Dual antiplatelet therapy after percutaneous coronary intervention: entering the final chapter?